With optimal treatment, myeloma isn't immediately life-threatening. Many patients live for years after their diagnosis, often ...
Learn how KMA and LMA represent a breakthrough in treatment approaches for multiple myeloma and related disorders.
Researchers show for the first time that engineered human plasma B cells can be used to treat a disease—specifically leukemia—in a humanized animal model. The results mark a key step in the ...
Researchers headed by a team at Seattle Children’s Research Institute have shown for the first time that engineered human plasma B cells can be used to treat a disease—more specifically leukemia—in a ...
Osaka, Japan – Vaccine effectiveness relies on creating a strong antibody response that can be reactivated to fight future infections. Now, researchers from Japan report that antibody-producing cells ...
Thromboembolic events in immunomodulatory drug (IMiD)–sparing regimens for patients with newly diagnosed multiple myeloma (NDMM). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results